22 results match your criteria: "Nobel Hospital[Affiliation]"

Intraoperative bleeding poses a substantial challenge, particularly in neuro-spine surgeries leading to complications such as hematomas, infections, and hemodynamic instability. Despite their proven efficacy, use of topical hemostatic agents (THAs) lacks comprehensive published literature and guidelines particularly in the Indian setting. The present study provides the first-ever Indian expert panel recommendations for effective adjunct THA use in different intraoperative bleeding sites and situations in neuro-spine surgeries.

View Article and Find Full Text PDF

Idiopathic Intracranial Hypertension: A Case Report.

JNMA J Nepal Med Assoc

February 2021

Department of Ophthalmology, Patan Academy of Health Sciences, Lagankhel, Lalitpur, Nepal.

Idiopathic Intracranial Hypertension is a rare occurrence in young, physically fit male and a diagnosis of exclusion among most patients presenting with signs and symptoms of raised intracranial pressure. Here we describe a case of a young male in the ideal weight range with no previous exposure to offending chemicals presented with a history of headache, obscuration of vision, and photopsia. On examination, there were no positive neurological findings.

View Article and Find Full Text PDF

The quality of instruments plays a pivotal role in governing safe operating room culture. The reprocessing system followed in the institution determines their durability thereby ensuring patient safety as well as minimizing health spending. Rigorous reprocessing in a centralized instrument reprocessing department by well trained staff following formulated guidelines helps to achieve the target of "safe surgery saves lives" as formulated by the World Health Organization.

View Article and Find Full Text PDF

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.

J Glob Oncol

September 2018

Ricardo Fernandes, Mohamed F.K. Ibrahim, Shaan Dudani, Kirstin Perdrizet, Habeeb Majeed, and Risa Shorr, The Ottawa Hospital; Ricardo Fernandes, Shaan Dudani, Kirstin Perdrizet, Habeeb Majeed, Brian Hutton, Dean Fergusson, and Mark Clemons, University of Ottawa; Sasha Mazzarello, Carol Stober, Lisa Vandermeer, Brian Hutton, Dean Fergusson, and Mark Clemons, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; and Bishal Gyawali, Nobel Hospital, Sinamangal, Kathmandu, Nepal.

Purpose: Despite widespread use of fluorouracil, epirubicin, cyclophosphamide, docetaxel (FEC-D) chemotherapy in breast cancer, the optimal strategy for primary febrile neutropenia (FN) prophylaxis remains unknown. A systematic review was therefore performed.

Methods: Embase, Ovid MEDLINE, PubMed, Cochrane Database of Systematic Reviews, Cochrane Register of Controlled Trials, and conference proceedings were searched from 1946 to April 2016 for trials that reported the effectiveness of primary FN prophylaxis with FEC-D chemotherapy.

View Article and Find Full Text PDF

Receipt of hematopoietic cell transplantation (HCT) can improve overall survival in older patients with intermediate or high-risk acute myeloid leukemia (AML); however, utilization of HCT is poor. It is important to understand the factors that affect the receipt of HCT in a real-world setting among the older patients. We utilized the National Cancer Database to determine receipt of HCT in older patients (61-75 years) with intermediate or high-risk AML reported between 2003 and 2012.

View Article and Find Full Text PDF

Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries.

J Glob Oncol

April 2017

, Nobel Hospital, Kathmandu, Nepal; and , Monash University, Clayton, Victoria, Australia.

Bevacizumab became the first molecular antibody to show survival benefit in advanced cervical cancer. In the GOG-0240 (Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer) trial, it improved overall survival by a significant 3.7 months over platinum doublet chemotherapy alone.

View Article and Find Full Text PDF

Low-value practices in oncology contributing to financial toxicity.

Ecancermedicalscience

March 2017

Department of Hemato-Oncology, Nobel Hospital, Sinamangal, Kathmandu 21034, Nepal.

Financial toxicity of cancer treatment is now a well-recognised problem in cancer medicine leading to patient bankruptcy and even poor survival, including in high-income countries and countries with public health care systems. Many oncologists, despite acknowledging the severity of financial toxicity as a problem, resign the responsibility of reducing the costs of cancer treatment to the government, industry, and oncology societies. However, an oncologist can play an important role in reducing the costs of cancer treatment because all cancer treatment decisions are made between the oncologist and the patient.

View Article and Find Full Text PDF

Drugs that lack single-agent activity: are they worth pursuing in combination?

Nat Rev Clin Oncol

April 2017

Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Sciences University (OHSU), 3181 South West Sam Jackson Park Road, Portland, Oregon 97239-3098, USA.

View Article and Find Full Text PDF

The risk of acute and chronic graft-versus-host disease (GVHD) with haploidentical transplant with post-transplant high-dose cyclophosphamide may be lower compared with matched unrelated donor transplant and largely similar to matched related donor transplant. The lower probability of GVHD with the haploidentical donor may result in a risk of nonrelapse mortality that is at least similar to or even lower than the matched donor. The incidence of relapse and survival are also largely similar to different donor types.

View Article and Find Full Text PDF

Tyrosine-kinase inhibitors (TKIs) represent the only hopes for long-term survival for patients with chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours. Thus, uninterrupted use of TKIs is of importance in such patients. Pure red cell aplasia (PRCA) is a rare disorder, not previously known to be associated with TKIs.

View Article and Find Full Text PDF

Should low-income countries invest in breast cancer screening?

Cancer Causes Control

November 2016

Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Japan.

With the increase in incidence and mortality of breast cancer in low-income countries (LICs), the question of whether LICs should promote breast cancer screening for early detection has gained tremendous importance. Because LICs have limited financial resources, the value of screening must be carefully considered before integrating screening programs into national healthcare system. Mammography-the most commonly used screening tool in developed countries-reduces breast cancer-specific mortality among women of age group 50-69, but the evidence is not so clear for younger women.

View Article and Find Full Text PDF

Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016.

Ecancermedicalscience

September 2016

Department of Haemato-Oncology, Nobel Hospital, Kathmandu 21034, Nepal.

Immuno-oncology has changed the landscape of cancer treatment in recent years. Immune checkpoint inhibitors (ICI) have shown survival advantage with long term remissions in a variety of cancers. However, there is another approach to harnessing the power of the immune system in combating cancer: the adoptive cell therapy (ACT) strategy.

View Article and Find Full Text PDF

Negative trials in ovarian cancer: is there such a thing as too much optimism?

Ecancermedicalscience

September 2016

Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, USA; Department of Public Health and Preventive Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon, USA; Center for Health Care Ethics, Oregon Health and Science University, Portland, Oregon 97239, USA.

Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results, the studies concluded optimistically in favor of the new agents under study.

View Article and Find Full Text PDF

Same Data; Different Interpretations.

J Clin Oncol

November 2016

Bishal Gyawali, Nobel Hospital, Sinamangal, Kathmandu, Nepal; Vinay Prasad, Oregon Health and Sciences University, Portland, OR.

View Article and Find Full Text PDF

Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.

Crit Rev Oncol Hematol

June 2016

School of Clinical Sciences & Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria 3800, Australia. Electronic address:

Docetaxel (DTX) is a standard chemotherapeutic agent for metastatic castration resistant prostate cancer (mCRPC). However, given a number of toxicities associated with DTX, considerable debate exists regarding the optimal number of DTX cycles to be administered in this setting. In clinic, it is a usual practice to continue DTX until toxicities or disease progression precludes its administration.

View Article and Find Full Text PDF

Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.

J Glob Oncol

June 2016

, Nobel Hospital, Kathmandu, Nepal; , Civil Service Hospital, Kathmandu, Nepal; and , Monash University, Clayton, Victoria, Australia.

Chemotherapy-induced nausea and vomiting (CINV) is a common challenge in oncology practice for which there are expensive guideline-based treatment options. Although supportive care in cancer adds significantly to the overall cost, the discussion of unaffordability of anticancer treatment frequently only revolves around the targeted drugs and immunotherapies. In this review, we highlight the available cost-saving strategies and recent updates in preventing CINV in patients with cancer.

View Article and Find Full Text PDF

Me, Too.

J Glob Oncol

June 2016

Department of Hemato-Oncology, Nobel Hospital, Sinamangal, Kathmandu, Nepal.

View Article and Find Full Text PDF

A live attenuated influenza A(H1N1)pdm 2009 vaccine was developed and distributed in India in 2010. We estimated the vaccine effectiveness (VE) against laboratory-confirmed pandemic H1N1 (pH1N1) infections in patients with influenza-like illness who visited five tertiary care hospitals in Pune, India during June-December 2010. Swab specimens were analyzed for influenza pH1N1 by reverse transcriptase polymerase chain reaction (RT-PCR).

View Article and Find Full Text PDF